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ABSTRACT 
Ten NB-acetylspermidine analogues were synthesized. These 
compounds were used as active site directed agents to investigate the 
catalytic mechanism of NB-acetylspermidine deacetylase. This enzyme is 
present in the cytosolic fraction of rat liver homogenate. 
The Ki values for all the compounds were determined from Dixon 
plots. The results of this study show that these compounds act as 
competitive inhibitors of NB-acetylspermidine deacetylase. The Ki 
values of these compounds range from 29.2 to 0.00018 mM. 
The size of the active site was investigated by substitution of the 
acetyl group of N-acetyl-1,6-diaminohexane and N-acetyl-1,8-diamino-
octane with larger groups. These modifications resulted in a decrease 
in the inhibitory activity. Compounds were made in which the length of 
the carbon chain between two terminal amino groups was varied. It was 
found that a six carbon separation is needed for optimal activity. 
Bioisosteric replacement of N4 of NB-acetylspermidine with a -cH2-
group resulted in a decrease in the potency of the compound compared 
with N-acetyl-1,6-diaminohexane. On the other hand, bioisosteric 
replacement of the N8 of NB-acetylspermidine with a -CH2- group resulted 
in a large increase in the inhibitory activity. The Ki value for this 
compound (Ki = 0.00018 mM) is lower than the Km of the enzyme (Km = 
0.01m mM). 
Results obtained from this project and other results obtained in 
our laboratory were used to draw a hypothetical model for the active 
site of NB-acetylspermidine deacetylase. 
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The aliphatic polyamines, putrescine, spermidine and spermine are 
normal cell constituents that play an important physiological role in 
living tissues. They are highly basic compounds (pKa range between 8 
and 11) that influence the growth and differentiation of the cells. 
The term polyamine applies to any compound that contains two or 
more amine groups in its structure. Structures of different polyamines 
are given in Figure 1. 
Discovery of Polvamines 
Antoni Van Lewenhoeck (1) was the first to detect spermine 
phosphate in human semen in 1678. Spermidine and spermine derived their 
names from human semen from which they were first isolated (2). In the 
hundred years after its detection, spermine phosphate was detected in 
various body organs and fluids (such as liver, spleen, and sputum) and 
was reported under different names (3,4,5). In 1878 various derivatives 
of spermine were prepared by Schreiner (5). 
The name putrescine was taken from the term putrefaction and is 
derived from the observations that it is rapidly formed in animal 
tissues under bacterial decomposition. The structur'e of spermine was 
obscure for many years in spite of the efforts of many scientists and 
only in 1924 was the right structure of spermine deduced (6). Once the 
structure was known, several methods were reported for the synthesis of 
the compound and its derivatives (7,8,9). 
Rosenheim and co-workers (10) were the first to prove that spermine 
-~- --~---, -' --~~--C 
A: H2 N-CH2-CH2-CH 2-NH2 
1 .. 3-Di umi nopropane 
B: H2N-CH2-CH2-CH2-CH2-NH2 
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C:. H2N-CH2-CH2-CH2-CH2 -CH 2-NH2 
Cadaverine 
0: H2 N-( CH2 ) 3-NH-( CH2 )4 -NH 2 
Spermidine 
E: H 2N-( CH 2 l3 -NH-( CH 2 )4 -NH-( CH 2l 3 -NH 2 
Spennine 
Figure 1. Structures of various polyamines 
2 
3 
isolated from human semen was identical with the base isolated by 
similar methods from various tissues and organs. During the synthesis 
of spermine, Dudley et al. (11) obtained another basic product. The 
compound was identified as spermidine. After the elucidation of its 
structure, spermidine was found to be widely distributed in cells. 
Distribution of Polyamines 
Polyamines are constituents of every kind of prokaryotic and 
eukaryotic cell. They are also one of the components of many viruses. 
These substances are intracellular constituents and are found only in 
small amounts in the extracellular fluids. 
Spermine and spermidine are more widely distributed in the tissues 
than putrecine (12). The concentrations of polyamines vary from one 
organ to another in a given species and from one species to another. 
The first study concerning the distribution of polyamines in human 
tissues was presented by Hamalainen (13). In that study spermine was 
precipitated as a phosphate salt and the weight of the precipitate was 
determined gravimetrically. This study revealed that human prostate and 
bone marrow contain higher amounts of spermine than kidney, lung and 
muscle. 
Neoplastic cells usually contain higher concentrations of 
polyamines than normal cells. Numerous studies have shown that 
polyamine levels are elevated in urine, serum, bone marrow cerebrospinal 
fluids and erythrocytes of many patients bearing tumors (14). It has 
been reported by many workers (15,16) that the levels of polyamines in 
rapidly growing cells are much higher than the levels present in non-
proliferating cells. Prokaryotic cells contain only spermidine and 
4 
putrescine. It has been found that putrescine is present in many organs 
and tissue fluids and these include liver (17), pancreas (18), and human 
semen (17). Siimes (19) had found that the level of polyamines in human 
organs ranges from 0.11 to 11.4 nmoles/mg protein depending on the organ 
used in the study. Cadaverine was found to be present in both bacterial 
and liver ribosomes (20). 
Little effort has been devoted to the study of polyamines in plants 
compared with that given to their study in humans and animals. The 
reason for the lack of interest in the study of polyamines in plants is 
not clear. 
In general, polyamines have been found to be present in many cell 
organelles such as ribosomes (21), mitochondria and chloroplast (21,22). 
Physiol_ogical Functions 
of Polyamines 
Polyamines are very important for the normal function of the body. 
The increase in polyamine concentrations is very important for cell 
proliferation. It is well documented that an increase in the ornithine 
decarboxylase activity and an increase in the level of putrescine and 
spermidine occurs in rat liver regenerating after partial hepatec-
tomy (23). Polyamines have been implicated in the regulation of nucleic 
acid metabolism (24,25,26). 
Aliphatic polyamines, putrescine, spermine and spermidine are 
strongly basic substances. At physiological pH, they are positively 
charged. Due to their cationic properties and structural charac-
teristios, polyamines are able to bind \vith ionic groups on nucleic 
acids, proteins and phospholipids through electrostatic interactions 
(27,28). They can also bind to those molecules through hydrogen and 
--- ~ ~---~~--~------
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hydrophobic bonds. Tabor (29) has reported that polyamines protect 
DNA against heat denaturation. Many workers (30,31) have found that 
polyamines stabilize ribosomes and tRNA. 
Sara et al. (325 have reported that the decrease in the basicity or 
hydrogen bonding capacity of putrescine resulted in a marked reduction 
in the stimulatory activity of putrescine on growth and protein 
biosynthesis of polyamine-depleted cultures. He suggested that two 
primary amino groups are needed in the polyamine structure for full 
activity. 
There have been many studies on the effect of polyamines on DNA and 
tRNA. These studies include the effect of polyamines on the stability 
of nucleic acids (33), on transcription (34) and on translation (35). 
In many cases magnesium ions may be substituted for polyamines, but 
there are cases of biochemical reactions in which polyamines are 
specific in their reactions. In another study, it has been found that 
the affinity of ribosomes for polyamines is reduced in the presence of 
magnesium ions {36). Polyamines offer advantages in biological systems 
over cationic ions such as ca++ and Mg++. One of their advantages is 
that polyamines are synthesized by the body and their level can be 
regulated and adjusted to the needed concentration. In contrast Mg and 
Ca ions have to be supplied in an absorbable form and they have to be 
transported across the cells' membranes. Recently, the effect of 
polyamines on the uptake of neurotransmitters has been studied {37). On 
the basis of these studies, it was concluded that polyamines inhibit the 
uptake of dopamine {DA) and choline by rat forbrain synaptosomes. The 
uptake of (GABA) is also inhibited but to a lesser extent than other 
neurotransmitters. 
In the future, additional physiological functions of polyamines 




Polyamines, at physiological pH, are positively charged and for 
6 
this reason they do not readily cross the blood brain barrier. In order 
to see their effects on the central nervous system (CNS) after intra-
peritoneal or intravenous injections, high doses have to be given. 
The effect of spermine and spermidine on body temperature has been 
investigated (38,39,40). These compounds have been found to produce 
hypothermia when they are administered intraperitoneally or intra-
cerebrally. In animals injected with 40 ug of spermine intracerebrally, 
the body temperature dropped, with a maximum decrease of about 1° c, 
24 hours after the injection, and the hypothermic effect lasted for 
about 3 days (38). 
The pharmacology and toxicology of the acetylated and nonacetylated 
polyamines have been investigated by Alshabanah and Blankenship (41). 
From those studies, they concluded that spermine is more toxic to mice 
than spermidine and putrescine. They also found the onset of toxicity 
of both N1- and N8-acetylspermidine is much more rapid than that of the 
spermine, spermidine, and putrescine. The reason for this difference in 
the onset could be explained on the basis that the acetylated form of 
polyamines may cross the blood brain barrier much better than the 
corresponding nonacetylated form of polyamines. 
Both acetylated and nonacetylated polyamines produce hypothermia, 
sedation, muscle incoordination, decreased motor activity, clonic 
-~~~-------------------
convulsion and death which is due to respiratory arrest. In addition, 
polyamines (when they are injected at a lower dose level) produce 
anorexia and adipsia which last for about two days (42). 
Biosynthesis of Polyamines 
7 
The biosynthetic pathway for polyamines is illustrated in Figure 2. 
Polyamines biosynthesis in plants as in bacteria is somewhat more 
complicated than that in mammalian cells in that two constitutive 
pathways lead to putrescine biosynthesis. Putrescine may be formed 
directly, through ornithine decarboxylation by ornithine decarboxylase 
(ODC), or indirectly, through a series of intermediates following 
arginine decarboxylation (43,44). 
Mammalian cells can synthesize putrescine through decarboxylation 
of ornithine. This conversion is catalyzed by ornithine decarboxylase 
(45). This step appears to be the rate limiting step in the polyamine 
biosynthesis. Putrescine is converted to spermidine by the addition of 
an aminopropyl group. This conversion is catalyzed by spermidine 
synthase. The aminopropyl group is derived from methionine, which is 
first converted into 3-adenosylmethionine and then decarboxylated by the 
enzyme s-adenosylmethionine decarboxylase. Once it has been decarboxy-
lated, decarboxylated S-adenosylmethionine is committed to polyamine 
synthesis (46). 
To synthesize spermine an aminopropyl group must be added to 
spermidine. The source of this group is the same as that of the first 
aminopropyl group (decarboxylated s-adenosylmethionine). This step is 
catalyzed by an enzyme known as spermine synthase (47,48). Spermidine 
synthase, and spermine synthase are different enzymes and they are 




























H2N-(CH):s --NH-CH2· -CH 2 -CH2 -CH2 -NH-(CH 2 ) 3 ~NH 2 
Figure 2. The major pathway for the biosynthesis 
of polyamines in mammals. 
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Ornithine Decar~oxylase 
Ornithine decarboxylase is the rirst enzyme in the polyamine 
biosynthetic pathway. It is a unique enzyme because of its rapid 
induction and the very short half life. 
The very rapid induction of ornithine decarboxylase has been 
described by many workers (49). The enzyme is studied mainly in rat 
liver, where great increases in the activity of the enzyme are 
9 
observed. The enzyme can be induced by many drugs as well as by 
hormones. The maximum induction is reached within about four hours 
arter the stimulation. Figure 3 shows the effect of administration of 
growth hormone on the induction of ornithine decarboxylase (50). The 
increase in the activity of the enzyme, under a variety of conditions, 
is accompanied by a corresponding increase in the amount or ornithine 
decarboxylase protein. The induction can be inhibited by administration 
or actinomycine which is a protein synthesis inhibitor. It has been 
reported (51) that this enzyme represents only between 0.01-0.05% of the 
total cellular protein, even when maximally inducted. 
The halr lire of ornithine decarboxylase has been reported to be 
between 10-20 minutes (52). This short half life of ornithine 
decarboxylase has been attributed to its cellular runction as the rate 
limiting step in the polyamine synthesis. 
It has been found that addition of putrescine to mammalian cells in 
cultures causes a rapid decrease in the ornithine decarboxylase 
activity •. This decrease is due to the synthesis or a protein inhibitor 
(antizyme) to ornithine decarboxylase (53.54). This antizyme can 
specirically interact with ornithine decarboxylase and form an inactive 
enzyme-antizyme complex. The interaction between ornithine decarboxylase 
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Figure 3. Induction of ornithine decarboxylase 
by growth hormone in adult (o) and 
weanling (•) rats. 
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and the antizyme might be the mechanism by which ornithine decarboxylase 
is regulated (55). 
Inhibition of Ornithine 
Decarboxylase 
The precise physiological role of polyamines is not clear, although 
many studies have shown that these amines may be involved in the control 
of cell division and growth as well as DNA synthesis. One of the best 
ways to investigate the function of the polyamines is through inter-
ference with their synthesis. This can be done by the inhibition of 
ornithine decarboxylase, which is the rate limiting step in their 
synthesis. The. difficulties of this study are due to the fact that the 
enzyme is rapidly induced and has a very short half life. In addition, 
the activity of ornithine decarboxylase is partially regulated by the 
interaction between the enzyme and its antizyme. Substances which 
inhibit ornithine decarboxylase can be divided into two groups according 
to their mechanism of action. 
Competitive Inhibitors. Several compounds which bind to ornithine 
decarboxylase in a reversible way have been synthesized. Alpha-methyl-
ornithine, and alpha-hydrazinoornithine are examples of this class 
(56,57). The major disadvantage of these compounds is that they 
increase the half life of ornithine decarboxylase (58,59). The half-
life of ornithine decarboxylase in the presence and absence of alpha-
methylornithine was found to be 57 and 19 minutes respectively. It has 
been reported that the decrease in the degradation of the enzyme might 
be due to the ability of the competitive inhibitor to enter the active 
site of ornithine decarboxylase and thus block or slow its degradation 
by proteolytic enzymes (58). Another disadvantage of the competitive 
12 
inhibitors is that the duration of inhibition of polyamine synthesis 
depends on the drug half-life in the body. 
Irreversible Inhibitors. Alpha-difluoromethylornithine (DFMO) is 
an effective and specific inhibitor of ornithine decarboxylase (59,60, 
61). The inhibition has been reported to depend on the dose, time of 
contact with the enzyme, as well as on the type of the organ used in the 
study. An intraperitoneal dose of 100 mg/Kg of body weight of DFMO 
reduced the activity of ornithine decarboxylase by 90, 40, and 50% in 
the prostate, thymus, and testis respectively six hours after injection 
( 60). 
The acute oral median lethal dose (LD50) for DFMO has been found to 
be 5.0 g/Kg (46). Administration of total daily dose of 4 g/KG for 28 
days to mice has been found to have no effect on the body weight and no 
organ toxicity was found. The mechanism of action of this compound is 
illustrated in Figure 4. 
Polyamine Metabolism 
There is more than one enzyme involved in polyamine metabolism 
(62). It has been reported (63) that polyamine oxidase catalyzes the 
oxidation of both spermine and spermidine. These molecules are cleaved 
at the secondary amino group to yield 3-aminopropionaldehyde and 
putrescine from spermidine or spermidine from spermine. Oxidative 
deamination of putrescine by diamine oxidase leads to the formation of 
4-aminobutyraldehyde which on further oxidation yields gama-amino 
butyric acid (GABA). Study of conversion of putrescine to GABA in mouse 
·liver has shown that 2-3% of GABA was formed from putrescine (64). It 
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cortex homoginate enhanced conversion of putrescine to GABA. Seiler 
(65) has found that GABA which is formed from N-acetylputrescine was 
nearly twice as high as that formed from putrescine. These results 
indicate that monoacetylputrescine acts as a much better substrate for 
polyamine oxidase than putrescine. 
Monoacetylated derivatives of polyamines have been shown to be 
normal constituents of human urine (66). Abdel Monem and Ohno (67) 
examined the acetylated derivatives of polyamines in the urine of normal 
subjects and cancer patients. Their study revealed that N1-acetyl-
spermidine and N8-acetylspermidine were both present in all samples. 
However they were unable to detect N1-acetylspermine, N4-acetylspermine 
and N4-acetylspermidine. This study also shows that cancer patients 
excrete higher amounts of N1-acetylspermidine than N8-acetylspermidine. 
Acetylation of spermidine leads to the formation of two isomers, 
NB-acetylspermidine and N1-acetylspermidine. Spermidine was found to be 
converted to N8-acetylspermidine by an enzyme present in the chromatin 
of liver and kidney (68). On the other hand spermidine has been found 
to be converted to N1-acetylspermidine by a cytosolic enzyme (69). 
Putrescine and histones were not acetylated by this enzyme (N1-acetyl-
spermidine transferase). 
Spermidine N1-acetyltransferase converts spermidine and spermine to 
N1-acetylspermidine and N1-acetylspermine respectively. In this 
conversion acetylCoA is the doner of the acetyl group. Spermidine/ 
spermine N1-acetyltransferase has been shown to be the rate limiting 
enzyme for biodegradation of polyamines (70,71). In vivo N1-acetyl-
spermidine is converted to putrescine and N1-acetylspermidine and 
N1-acetylspermine is converted to spermidine; both reactions are 
----~-~---
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catalyzed by polyamine oxidase. 
The acetylated forms of polyamines are better substrates for 
polyamine oxidase than the nonacetylated polyamines (64). The enzymes 
spermidine synthase, spermidine N1-acetyltransferase and polyamine 
oxidase form a cycle for the interconversion of polyamines (72). This 
cycle is shown in Figure 5. 
Matsui et al, (73) studied the induction of the N1-acetyltransferase 
and found the activity of this enzyme was 2.5 times higher than the 
control when 50 ng/mL of phorbal 12-myristate-13-acetate was added to 
the lymphocyte suspension, In another study Matsui and Pegg (74) have 
shown the maximum induction of spermidine/spermine N1-acetyltransferase 
is reached after six hours of stimulation and this induction can be 
inhibited by addition of cycloheximide. The decrease in the activity of 
spermidine/spermine N1-acetyltransferase by addition of cycloheximide 
depends on the method used to induce the enzyme (73). Cycloheximide at 
about 50 uM caused a 72% reduction in the activity of the enzyme which 
had been induced by addition of parathyroid hormone (75). On the basis 
of the above results it seems that the increase in the activity of 
N1-acetyltransferase is regulated by changing the rate of the synthesis 
of the enzyme. 
Further degradation of acetylated polyamine has been studied both 
in vitro (76) and in vivo (77). The results of these studies show that 
NB-acetylspermidine was deacetylated to spermidine by an enzyme present 
in the cytosol of the rat liver. However, N1-acetylspermidine has been 
found to be not deacetylated by this enzyme, but it is good substrate 
for polyamine oxidase (63,78). The latter enzyme converts N1-acetyl-













Figure 5. Route of the synthesis and metabolism of spermidine 
in rat liver. The enzymes involved are I) ornithine 
decarboxylase; 2) spermidine N 1-acetyltransferase; 
3) polyamineoxidase; 4) spermidine synthase; 
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Manneh and Blankenship (79) have found the Km for NB-acetyl-
spermidine deacetylase to be 0.01 roM. Diisopropylfluorophosphate was 
tested and found to be a poor inhibitor (Ki=33 mM) for the enzyme. 
These results indicate that the active site of the enzyme does not have 
a serine hydroxyl group. On the other hand, the enzyme was found to be 
inhibited by 1,10-orthophenanthroline (Ki=1.25 mM) which is reported to 
be a specific inhibitor for enzymes containing zinc or copper in their 
active sites (80). 
Clinical Application of 
Polyamine Antimetabolites 
The association of rapid cell growth with an increase in ornithine 
decarboxylase activity has been known for many years. Accumulation of 
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putrescine, spermidine, and spermine usually follows the increase in the 
activity of ornithine decarboxylase. As a result of this, inhibition of 
polyamine biosynthesis via inhibition of ornithine decarboxylase might 
be a means for chemotherapy of disease states characterized by rapid 
cell multiplication. 
Inhibition of ornithine decarboxylase by DFMO has a striking effect 
on the embryonic development (81). It has been shown that animals 
receiving -DFMO (2% in drinking water) during 5-8 days of gestation 
arrested embryonic development. This arrest correlated with the 
decrease of ornithine decarboxylase activity and with putrescine and 
spermidine depletion in the uterus. 
DFMO is also effective against Trypanosoma brucei brucei (T. b. 
brucei). Inoculation of mice with 5 x 105 T. b. brucei killed the 
animal five days after the infection. However, treating the infected 
animals with 1 or 2% of DFMO solution in their drinking water resulted in 
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curing the animals (82). T. b. brucei starts to disappear from the 
blood of the infected animals five days after administration of DFMO. 
Injection of suspensions of the brain from cured animals failed to 
induce infection in the healthy animals. However, administration of 
putrescine, spermidine, and spermine along the DFMO abolished its effect 
(83). All these suggest that DFMO influences parasites' proliferation 
by the depletion of polyamines. 
In order to cure groups of mice infected with 2-5 x 105 T. b. 
brucei, 3 mg/Kg of bleomycin (i.p.) or 1% of DFMO (in drinking water) 
was needed. However, coadministration of 0.25 mg/Kg of bleomycin with 
0.25% DFMO resulted in cured animals (84). These values represent about 
25 and 8% of the curative dose of DFMO and bleomycin respectively. 
These and other results suggest that there is synergism between DFMO and 
bleomycin (84). 
DFMO at 5 ru4 has been shown to retard the growth rate of EMTS6, a 
murine mammary sarcoma in tissue culture (85). Combined treatment of 
this mammary sarcoma with DFMO and cyclophosphamide caused a reduction 
in the tumour weight greater than either treatment alone. 
Sequential administration of DFMO and methylglyoxal bis (guanyl-
hydrozone) (MGBG) resulted in an apparent synergism when tested in 
childhood leukemia (86). Even though there is an increase in the 
therapeutic response of the combined drugs, there was no increase in the 
side effects of those compounds. The increase in the therapeutic 
response has been shown to result from the enhancement of the cellular 
uptake of MGBG (86). The effect of combined treatment of DFMO and 
adriamycine on the 1120 leukemia and EMT6 tumors in mice has been 
studied by Jacques et al. (87). The results of this investigation have 
i 
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shown that combined treatment with these drugs caused a great reduction 
(60%) in tumor weight. 
Interference with polyamine biosynthesis caused a decrease in the 
growth rate of Eschirichia coli and Pseudomona aeruginosa. Bacteria are 
capable of synthesizing polyamines through decarboxylation of ornithine 
by ornithine decarboxylase and through decarboxylation of arginine by 
arginine decarboxylase (88). The combined addition of alpha-monofluoro-
methylornithine (an irreversible inhibitor of arginine decarboxylase) to 
E. coli and Ps. aeruginosa cultures had been found to increase the mean 
doubling time of those organisms (88,89). Addition of 0.1mM putrescine 
and 0.1 mm spermidine to the cultures of the above named organisms 
abolishes the effect of those inhibitors. 
It is apparent that DFMO alone or in a combination with other drugs 
has strong potential for chemotherapy of many diseases. This new 
approach to treatment will give hope to those who suffer from T. b. 
brucei, leukemia, and many other diseases. 
Goal of the Proiect 
NS-acetylspermidine has been shown to be synthesized in a chromatine 
catalyzed reaction (69,90). Analysis of human urine has indicated that 
this compound is present in the urine of cancer and noncancer indivi-
duals (67). Blankenship (77), in his investigation, has reported that 
NB-acetylspermidine is present in spleen tissue at a concentration of 
only 1.0 ng/g, The absence of detectable level of Ne-acetylspermidine 
in the liver and kidney tissues does not rule out their presence in 
those tissues. The absence of detection might be due to the low concen-
trations relative to the sensitivity of the detection technique (77). 
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Study of the metabolism of N8-acetylspermidine has indicated that 
it is deacetylated in the cytosol fraction of the rat liver (76,78). 
Inhibition of the N8-acetylspermidine deacetylase enzyme will result in 
an increase in the level of N8-acetylspermidine. An inhibitor to this 
enzyme would provide a useful tool to find out the physiological 
functions of N8-acetylspermidine and deacetylation process. 
The purpose of this project is to prepare competitive inhibitors 
for N8-acetylspermidine deacetylase. These compounds will be used to 
obtain information about the catalytic nature of the active site of the 
enzyme.- Information gained from the activity of the above inhibitors 
will be used to design an irreversible inhibitor for the N8-acetyl-
spermidine deacetylase. Finally these inhibitors will be used to 
inhibit N8-acetylspermidine deacetylase in Physarum polycephalum (slime 
mold) and in rats. These studies should give information on the 
function of N8-acetylspermidine in microorganisms and in mammalian cells. 
I 
MATERIALS AND METHODS 
Chemicals. 1,6-Diaminohexane and 1,8-diaminooctane were purchased 
from the Sigma Chemical Company. Putrescine, butyryl chloride, acetic 
anhydride, triethylamine, methanesulfonyl chloride, cadmium chloride, 
6-bromohexanoyl chloride, methylmagnesium bromide, 2-(tert-butoxy-
carbonyloxyimino)-2-phenylacetonitrile (BOC-ON), and chloroacetic 
anhydride were purchased from the Aldrich Chemical Company. 
All the solvents were ACS reagent grade and were used without 
further purification unless otherwise stated. 
Instrumentation. Melting points were recorded in open capillary 
tubes on a Thomas-Hoover apparatus and are uncorrected. Infrared (IR) 
spectra were recorded on a Perkin-Elmer 283 instrument. Nuclear 
magnetic resonance (NMR) spectra were recorded on a Varian XL-200 
spectrometer, in a 5 mm probe using n2o as a solvent and the water peak 
as a reference line. 
Elemental analyses (C,H,N) were performed at the microanalytical 
laboratory of the National Institutes of Health (NIH), Bethesda, 
Maryland. Mass spectra were conducted on a Hitachi Perkin-Elmer RM3-4 
mass spectrometer (CI,70 eV). 
Glassware. All the glassware used was treated by the following 
procedure: Visually clean glassware was completely immersed at room 
temperature in a solution of the nonionic detergent (Alconox, INC) in 
tap-water for about 30 minutes. It was then washed and rinsed not less 
than five times in running tap water followed by two separate rinses 
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with distilled water and one rinse with acetone. Following washing, 
rinsing and drying in air, all the glassware was dried in a hot air 
drying oven at 110°C (Radiant Heat oven, Lab Instruments, INC). 
Chromatography 
Ion-Exchange Chromatography. Amberlite (100 g) ion exchange resin 
CG-50 (wet mesh 100-200) was transferred into 100 mL flask. The resin 
was washed alternately with 350 mL of 3 N HCl and 3 N NH40H. The wash 
was repeated 3 times. The resin was then rinsed not less than two times 
with distilled water and its pH was brought to 9-9.5 with NH40H as 
measured on a pH meter (Corning Scientific Instruments). The washed 
resin was added to a column 65 x 2.5 em and allowed to settle for about 
2 hours. After packing the resin, it was washed with distilled water 
until the wash became clear. About 40 mL of the reaction mixture was 
transferred to the column, and the elution was carried out with 150 mL 
distilled water, followed by 250 mL of 0.5 N NH40H and 100 mL of 2 N 
NH40H. The elution flow rate was adjusted to 1-2 mL/minute. During the 
elution with 2 N NH40H, fractions of 10 mL were collected and analyzed 
by thin layer chromatography (TLC). 
TLC plates were developed in a mixture of methanol, chloroform, and 
NH40H (10:10:1). Fractions which were found to contain the wanted 
compound were collected, combined and the solvent was removed by 
evaporation using a rotc-evaporator (Brinkmann Instrument Company). 
Thin Layer Chromatography: 
TLC plates were developed in a mixture of methanol, chloroform and 
NH40H (10:10:1). All TLC plates were Merk E. Merk (60 F- 254), 5*10 em, 
silica layer 0.25 mm thick. Visualization, unless otherwise mentioned, 
was accomplished by ninhydrin~ 
Absorption Chromatography 
Silica gel, (200 g, 230-400 mesh EM), was transferred into a 20 mL 
beaker. Approximately 600 mL of CH2Cl2 was added, and mixed well. The 
slurry of the silica gel was added to a column 65 x 3.5 em and allowed 
to settle for about one hour. After packing the silica, 50 mL of the 
reaction mixture was transferred to the column and the elution was 
carried out with a mixture of methanol, CH2c12 , and concentrated NH40H 
(7:5:1). Fractions (10 mL) were collected and those found to contain 
the desired compound were combined and the solvent was removed by 
evaporation using a rotary evaporator. 
Crystallization 
The oily residue was dissolved in 10-15 mL of distilled water and 
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the pH was brought to 2 using 3 N HCl. This was evaporated on a rotary 
evaporator and the residue dried on vacuum pump (The Welch Scientific 
Company). The hydrochloride salt was dissolved in a hot 2-propanol. 
The solution was filtered, concentrated and allowed to crystallize at 
40 c. The crystals were collected by filtration and stored in a 
desiccator. 
Enzvme Assay 
Male Wister rats, 140-180 g, were sacrificed by decapitation and a 
100,000 x g supernatant fraction (cytosole) was prepared from 5 g of the 
rat liver as has been described by Blankenship (76). Tritium labeled 
NB-acetylspermidine (3H-acetyl), (2.5-12.5 nM) was mixed with different 
concentrations of the potential inhibitor and with 100 uL of the cytosol 
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fraction in a final volume of 0.5 mL. The incubation mixture consisted 
of sucrose (0.125 mM), NaH2P04 (29 uM), ~~c12 (25 uM) at pH 7.0. The 
incubation was carried out for 10 minutes at 37°C in a shaking water 
bath (Dubnoff incubator). The reaction was stopped by addition of 
0.5 mL of 1 N HCl containing 0.05 M acetic acid to the mixture. Ethyl 
acetate (3 mL) was added to each of the test tubes. The tubes were 
shaken for 10 minutes using an Eberbach shaker and then centrifuged for 
5 minutes at 1500 x g using IEC Model 2 K centrifuge. The organic layer 
of the supernatants (2 mL) were transferred to counting vials to each of 
which was added 10 mL of scintillation cocktail which had been prepared 
by mixing 0.66 liter triton X-100, 1.34 liter toluene, 7.32 g of 2,5-di-
phenyloxzole and 1.32 g of p-bis(2-(5-phenyloxazole))benzene. The 
radioactivity of the radiolabeled acetic acid released by deacetylase 
activity was measured with a liquid scintillation counter (Beckman 
CPM-100). 
The control was run under the same conditions as the tested 
compounds and contained all the reaction components except the cytosol 
fraction. All the reactions were run in triplicate unless otherwise 
stated. The Ki of each inhibitor was determined by using a Dixon plot 
(90). 
Synthesis 
N-Butyryl-1,4-diaminobutane Hydrochloride. Putrescine (10 g, 
0.113 mol) was dissolved in 50 mL of acetonitrile. Butyryl chloride 
(10.65 g, 0.099 mol) was mixed with 20 mL of acetonitrile and was added 
to the reaction flask in a dropwise manner. The reaction was stirred at 




layer was evaporated and the residue was dissolved in 100 mL of 
distilled water, This solution was brought to pH 2 by using 3 N HCl and 
then extracted with CHC13 (3 x 50 mL). The water layer was added to an 
ion-exchange column and treated as has been described on p, 22-23. The 
yield was 4.0 g (25%), mp 139-141° c. IR (mineral oil) 1640 cm-1 (C:O), 
broad (+NH3) N-H stretch, 3300-2000 cm-1 and asymmetric (+NH3) N-H bend, 
1610 cm-1. NMR: ppm 0.85 (3H,t), 1.5 (6H,t), 2.1 (2H,t), 2.9 (2H,t), 
3.1 ( 2H, t). 
Anal. 
Calculated. C, 49.35; H, 9.83; N, 14.39. 
Found. C, 49.60; H, 9.75; N, 14.67. 
Mass Spec, CI, M + 1= 159.0 (for the base). 
N-Acetyl-1.8-diaminooctane Hydrochloride, Five grams of 
1.8-diaminooctane (0.035 mol) was dissolved in 40 mL of acetonitrile. 
Acetic anhydride (3.3 g, 0.035 mol) was mixed with 15 mL of acetonitrile 
and was added dropwise to the reaction flask. The reaction was stirred 
under a nitrogen atmosphere at room temperature for 3 hours. The 
organic layer was evaporated and the residue was dissolved in 150 mL of 
distilled water. The mixture was adjusted to pH 2 with 3 N HCl and then 
extracted with ether (2 x 30 mL). The aqueous layer was concentrated to 
about 50 mL and then transferred to an ion-exchange column. The 
compound was eluted with NH40H and crystallized as has been described on 
p. 23. The yield was 2.2 g (28%), mp 131-133°C, IR (mineral oil) 1640 
cm-1 (C=O), broad (,+NH3) NH stretch 3300-2000 cm-1, and asymmetric 
(+NH3) NH bend 1570 cm-1. NMR: ppm 1.85 (3H,s), 2.85 (2H,t), 3.05 
(2H,t). 
26 
Anal. c1 0H23N20Cl (M.W = 222.76). 
Calculated. c, 53.92; H, 10.40; N, 12.57. 
Found. c, 53.82; H, 10.19; N, 12.23. 
Mass Spec. CI, M + 1 = 187 (for the base). 
N-Acetyl-1.6-diaminohexane Hydrochloride. Acetic anhydride (7 g, 
0.07 mol) in 15 mL of benzene was added dropwise to 1,6-diaminohexane 
(8 g, 0.07 mol) in benzene (15 mL). The reaction was allowed to run 
under nitrogen atmosphere for 3 hours at room temperature and with 
continuous stirring. The solvent was removed in vacuo and the residue 
was dissolved in 200 mL of distilled water. This solution was brought 
to pH 2 by using 3 N HCl and extracted with CHC13 (3 x 50 mL). The 
aqueous solution was concentrated and applied to an ion-exchange 
column. The compound was eluted with NH40H and crystallized as has been 
described on p. 22-23. The yield was 3.0 g (22%), mp 130-131°C. IR 
(mineral oil) 1650 cm-1 (C=O), broad (+NH3) NH stretch 3300-2000 cm-1, 
and asymmetric (+NH3) NH bend 1570 cm-1. NMR. ppm 1.85 (3H,s), 2.85 





C8H1gN20Cl (M.W = 158.25) 
C, 49.30; H, 9.83; N, 14.38 
C, 49.11; H, 9.88; N, 14.17 
CI, M + I= 194.70 (for the base). 
N-Acetyl-1.10-diaminodecane Hydrochloride. This compound was 
synthesized and isolated by the same procedure described on p. 25. In 
this synthesis, acetic anhydride (3.0 g; 0.035 mol) in 15 mL of benzene 
was added dropwise to the 1,10-diaminodecane (6 g; 0.035 mol) in 200 mL 
of benzene. The yield was 4.0 g (46%), mp 101-103° c. IR (mineral oil) 
i 
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1650 cm-1 (C=O), broad (+NH3) N-H stretch 3370-2000 cm-1, asymmetric 
(+NH3) N-H bend 1540 cm-1. NMR. ppm 1.85 (3H,s), 2.85 (2H,t), 3.5 
(2H, t). 
Anal. c12H27N20C1 (M. W. = 250.81). 
Calculated. c, 57.46; H, 10.85; N, 11.16. 
Found. c, 57.30; H, 10.69; N, 11.12. 
Mass Spec. CI, M + 1 = 215 (for the base). 
N-Methanesulfonyl-1,8-diaminooctane Hydrochloride. A stirred 
solution of 1,8-diaminooctane (3.0 g, 0.02 mol) in benzene (50 ml) was 
treated dropwise with metbanesulfonyl chloride (2.2 g, 0.02 mol). The 
reaction was allowed to run for about 2 hours with continuous stirring 
at room temperature. The solvent was removed in vacuo and the residue 
was dissolved in 200 mL distilled water. To this was added 3 N HCl to 
pH=2 and the solution was filtered. The aqueous solution was 
concentrated, and applied to an ion-exchange column. The compound was 
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eluted as usual with 2 N NH40H and crystallized as has been described on 
p. 22-23. The yield was 2.41 g (47%), mp 132-134° c. IR (mineral oil) 
asymmetric (S=O) stretch, 1380 cm-1, symmetric (S=O) stretch, 1155 cm-1, 
broad (+NH3) N-H stretch, 3300-2000 cm-1, and asymmetric (+NH3) N-H 





C9H23N20SCl (M.W. = 258.81). 
C, 41.76; H, 8.95; N, 10.82. 
C, 41.85; H, 8.86, N, 10.72. 
CI, M + 1 = 223 (for the base). 
N-Methanesulfonyl-1.6-diaminohexane Hydrochloride. This compound 
was prepared and isolated by the method described on p. 27. To a solution 
-··.--
of 1,6~diaminohexane (5.0 g, 0.04 mol) in benzene was added dropwise a 
solution of methanesulfonyl chloride (3.0 g, 0.02 mol) in 15 mL of 
benzene. The yield was 3.0 g (65.0%), mp 114-116° C. IR (mineral oil) 
asymmetrical (S=O) stretch, 1380 cm-1, symmetric (S=O) stretch, 1155 
cm-1, (+NH3) N-H stretch, 3300-2000 cm-1, and asymmetric (+NH3) N-H 
bend, 1600 cm-1. NMR: ppm 2.9 (2H,t), 2.95 (3H,s), 3.0 (2H,t). 
Anal. C7H19N202SCl ( M. W. = 230.76). 
Calculated. c, 36.43; H, 8.29; N, 12.13. 
Found. c, 36.50; H, 8.31; N, 12.11. 
Mass Spec. CI, M + 1 = 195 (for the base). 
Methyl N-(8-Aminooctyl)carbamate Hydrochloride. A solution of 
methyl chloroformate (1.9 g, 0.01 mol) in 15 mL of benzene was added 
d~opwise to a flask containing 1,8-diaminooctane (3.0 g, 0.01 mol) in 
150 mL of benzene. The reaction was stirred at room temperature and 
under nitrogen for 3 hours. The solvent was removed in vacuo and the 
residue was dissolved in 150 mL of distilled water. The solution was 
adjusted to pH 2 with 3 N HCl, filtered and extracted with CHCl3. The 
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aqueous solution was concentrated to about 40 mL and then transferred to 
an ion-exchange column. The compound was eluted with ammonium hydroxide 
and crystallized as has been described on p. 22-23. The yield was 2.5 g 
(52%), mp 131-133° c. IR (mineral oil) 1790 cm-1, (C=O) broad (+NH3) 
N-H stretch, 3380-1000 cm-1 asymmetric (+NH3) N-H bend, 1530 cm-1. NMR: 
ppm 2.85 (2H,t), 2.95 (2H,t), 3.5 (3H,s). 
Anal. (M.W. = 238.76). 
Calculated. C, 50.30; H, 9.70; N, 11.73. 
Found. C, 50.47; H, 9.66; N, 11.84. 
Mass Spec. CI, M + I = 203 (for the base). 
Methyl N-{6=Aminohexyl)carbamate Hydrochloride. This compound was 
obtained from 1,6-diaminohexane (5 g, 0.025 mol) and methyl chloro-
formate (2.36 g, 0.025 mol) by the same procedure described on p. 28. 
The yield was 2.5 g (48%), mp 140-141° c. IR (mineral oil) 1700 cm-1 
(C=O), broad (+NH3) stretch, 3370-2000 cm-1 and asymmetric (+NH3) N-H 
bend, 1535 cm-1. NHR: ppm 2.85 (2H,t), 3 (2H,t), 3.5 (3H,s). 
Anal. (M.W. = 210.70). 
Calculated. C, 45.56; H, 9.08; N, 13.29. 
Found. C, 45.54; H, 9.13; N, 13.29. 
Mass Spec. CI, M + 2 = 175 (for the base). 
N-Chloroacetyl-1,6-diaminohexane Hydrochloride. To 1,6-diamino-
hexane (4 g, 0.034 mol) in 100 mL of benzene was added a solution of 
BOC-ON (4 g, 0.016 mol) in 30 mL of benzene in a dropwise manner. The 
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reaction was stirred under nitrogen atmosphere at room temperature for 3 
hours. The solvent was evaporated in vacuo and the residue was 
dissolved in CHC13 and chromatographed over silica gel with a mixture 
CH30H, CHC13 and cone. NH40H (7:5:1). The eluent which appeared to 
contain only the product was collected and concentrated to dryness in 
vacuo. The residual oil (1.5 g) was dissolved in CHCl3 (150 mL) and was 
mixed with triethylamine (7 g, 0.07 mol). To the above mixture a 
solution of 0.5 g (0.004 mol) of chloroacetyl chloride in 30 mL of CHCl3 
was dripped into the stirred reaction mixture. Stirring was continued 
for 3 hours at room temperature and then the reaction mixture concen-
trated to dryness in vacuo. The product was crystallized from a mixture 
of benzene and hexane (5:3). The crystals (1.3 g) were collected and 
dissolved in 3 N HCl-EtOAc (5 mL). After 2 hours the solution was 
filtered and the precipitate was dissolved in hot 2-propanol. The 
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mixture was concentrated to mr., and was placed in a refrigerator. The 
crystals were collected by filtration. The yield was 0.70 g (20%), 
mp 80° C. IR (mineral oil) 1650 cm-1 (C:O), broad (+NH3) N-H stretch, 
3300-2000 cm-1, asymmetric (+NH3) bend, 1550 cm-2 and C-Cl,780 cm-1. 
NMR: ppm 2.85 (2H,t), 3.15 (2H,t), 4.0 (2H,s). 
Anal. (M.W. = 229.15). 
Calculated. C, 41.94; H, 7.91; N, 12.22. 
Found. C, 41.98; H, 7.95; N, 12.20. 
Mass Spec. CI, M + 1 = 193 (for the base). 
N-(3-aminopropyl)..;7-aminoheptane-2-one Hydrochloride. Methyl-
magnesium bromide (40 g, 2.80 mol) and 500 mL of anhydrous ether were 
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mixed in a 1000 mL round bottom flask cooled in an ice-bath and stirred 
slowly under a nitrogen atmosphere while 55 g (0.31 mol) of anhydrous 
cadmium chloride was added in portions during 10 minutes. After stirring 
for 30 minutes, the ice-bath was removed and stirring continued an 
additional 4 hours. To the brown solution of the organocadmium compound 
was added, in about one hour, a solution of 55 g (0.31 mol) of 6-bromo-
hexanoyl chloride in 150 mL of benzene. Slow stirring was continued at 
room temperature for about 15 hours. The resulting grayish-brown 
solution was stirred for an addition~~ hour with refluxing (during this 
period the solution becomes very viscous). Ice and 100 mL of 10% HCl 
were added and the solution was stirred for 2 hours. The organic layer 
was collected, dried over anhydrous sodium sulfate and distilled. The 
residue remaining after removing the organic solvents was distilled at 
90-95° C (0.1-0.05 mm Hg). The yield of 7-bromoheptane-2-one was 35 g. 
To 1,3-diaminopropane (18.4 g, 0.25 mol) in 150 mL of tetra-
hydrofuran (THF), 7-bromoheptane-2-one (12 g, 0.062 mol) in 50 mL of THF 
L 
was added in a dropwise mannero The reaction was allowed to run for 10 
hours with continuous stirring at room temperature. The solvent was 
removed in vacuo and the residue was dissolved in 120 mL of distilled 
water and applied to an ion-exchange column. The product was eluted 
with 2 N NH40H and crystallized as the hydrochloride salt salt from 
ethanol. The yield was 8.4 (52%), mp 210-215° c. 
31 
IR: broad (+NH3) N-H stretch 3100-2000 cm-1, asymmetric (+NH3) N-H 
bend 1610 cm-1 and 1720 cm-1 (C=O). NMR: ppm 1.25 (m,2H), 1.4-1.7 





(M.W. = 259.22). 
C, 46.29; H, 9.33; N, 10.80. 
C, 46.37; H, 9.35; N, 10.78. 
CI, M + 1 = 187 (for the base). 
DISCUSSION 
Chemistry 
All the 10 compounds were synthesized according to the outline in 
schemes 1, 2, 3 and 4. N-Butyrylputrescine was synthesized by modifica-
tion of Taber synthesis of N-acetylputrescine (91). Butyryl chloride 
was added to the putrescine in a dropwise manner. This procedure gave 
two products, N-butyrylputrescine and N,N'-dibutyrylputrescine. 
Purification of N-butyrylputrescine from the impurities by crystalliza-
tion from 2-propanol was unsuccessful. Ion-exchange chromatography was 
used to separate N-butyrylputrescine from the unreacted putrescine and 
from N,N'-dibutyrylputrescine. Putrescine binds much more strongly to 
the resine than the other two products. Binding of N-butyrylputrescine 
to the resine is much stronger than the binding of the N,N'-dibutyryl-
putrescine. The column was washed with water to remove all the salts 
and with 0.5 N NH40H to elute N,N'-dibutyrylputrescine. Ammonium 
hydroxide (2 N) was used to elute N-butyrylputrescine. 
The IR absorptions for N-butyrylputrescine (Figure 6) are consis-
tent with the expected structure showing most notably the C=O stretch at 
1640 cm-1 and broad (+NH3) N-H stretch at 3300-2000 cm-1. The NMR of 
this compound (Figure 7) exhibited all the expected absorptions. 
Protons A appeared as triplet at 0.9 ppm. Protons B appeared as a 
multiplet at 1.5 ppm. c, D and E protons appeared as triplets at 2.9, 
3.1, and 2.1 ppm respectively. C and D protons was deshielded by the 
combination effect of both N and o. However, the downfield shift of E 
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Figure 7. Nuclear magnetic resonance spectrum of 
N-butyrylputrescine hydrochloride (in D20), 
200 MHZ. 
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1 
the compounds the solvent peA~ appeared at 4.75 ppm. Du~~ et al. (92) 
has found the HDO resonance peak at 4.8 ppm. The integration was in 
agreement with the above assignments. The mass spectrum (Figure 8) is 
also consistent with the assigned structure showing the M + 1 peak at 
159 (M.W. = 158.25). 
Compound 2 was synthesized to determine the importance of the 
nitrogen in the 4-position for the binding of N-acetylspermidine to the 
N-acetylspermidine deacetylase. The N was replaced with the 
bioisosteric -CH- group. If this replacement does not affect the 
affinity of 2 for the enzyme, inhibitors with simpler structures could 
be designed and synthesized. 
Compounds 5 and 7 were designed to investigate the size of the 
active site of the enzyme. The acetyl group on the NB-position was 
39 
replaced with methanesulfonyl and with carbamyl groups. If the size of 
the active site of NB-acetylspermidine deacetylase is not critical and 
can accommodate these bioisosteric groups, these compounds should serve 
as inhibitors of the enzyme. 
Compounds 2, 5 and 7 were synthesized according to the schemes 1 
and 2. A solution of 1,8-diaminooctane in acetonitrile or in benzene 
was treated with an appropriate reagent. The reactions were run at room 
temperature and with continuous stirring. As in the synthesis of 
compound 1, this procedure gave two products in each reaction. The 
wanted compounds were purified by an ion exchange chromatography. The 
impurities were eluted with H20 and with 0.5 N NH40H. The wanted 
compound was eluted with 2 N NH40H. The yield of both compounds 5 and 7 
(47, 52%) was higher than that of compound 2 (28.21%). Crystallization 
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The IR absorption of compound 2 (Figure 9) showed strong absorption 
at 1640. cm-1 ( C=O) and broad (+NH3) N-H stretch at 3300-2000 em, 
asymmetric (+NH3) NH bend at 1610 cm-1. The spectrum showed a weak 
absorption at about 720 cm-1. This absorption is caused by a bending 
vibration of the (-CH2-) groups. The NMR of compound 2 is shown in 
Figure 10. The protons of the acetyl group appear as a singlet at 1.85 
________ PP_!llL_~rot_grg:_!Lan_d_J)_ a.pp~_a.r_ ~s_ triplets at 3.1 aQd 2. 9 ppm. The C 
protons appear as a multiplet between 1 and 2.1 ppm. The mass spectrum 
1 
(Figure 11) of this compound is also consistent with the assigned 
structure, showing a molecular ion peak at M + 1 = 187 (M.W. = 186.31). 
The IR for compound 5 (Figure 12) showed a strong asymmetrical 
stretching absorption at 1380 cm-1 (S=O) symmetric (SO) stretch at 
1155 em, a broad absorption (+NH3) N-H stretch at 3300-2000 cm-1 and a 
asymmetric (+NH3) N-H bend at 1610 em. A weak absorption appears at 
about 720 cm-1, and is characteristic for a (CH2) group where n > 4. 
The NMR spectrum of compound 5 (Figure 13) showed the characteristic 
peaks expected of the compound. The A protons appear as a singlet at 
2.95 ppm. The downfield shift of these protons is due to the effect of 
N,O and S (N-SO). Band D protons appear as tiplets at 3 and 2.9 ppm 
respectively. C protons appeared as a multiplet between 1.2 and 
2.1 ppm. The mass spectrum of this compound (Figure 14) showed the 
M + 1 pe~ at 223 (M.W. = 222.35). 
The IR for compound 7 (Figure 15) showed clearly the presence of 
the carbonyl group at 1690 em. Major absorptions are observed for 
(+NH3) N-H stretch at 3300-2000 cm-1, and asymmetric (+NH3) N-H stretch 
at 1610 cm-1. The spectrum also showed a weak absorption at about 
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Figure 9. Infrared spectrum of N-acetyl-tB-diaminooctane 
hydrochloride (in mineral oil). 
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Figure 10. Nuclear magnetic resonance spectrun1 of 
N -acetyl-1,8-diaminooctane hydrochloride 
(in D20), 200 MHZ. 
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Figure 11_ Chemical ionization (NH3) mass s]>ectrum of 
N-acetyl-1 .. 8-diaminooctane hydr~·chloride. 
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Figure 13. Nuclear magnetic resonance spectrurh of 
N-methanesulfonyl-1~8-diaminoctane , 
hydrochloride (in n2o>~ 200 MHZ. 
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Figure 14_ Chemical ionization (NH3) mass spe<,:trum of 
N-methanesulfonyl-1~ 8-diaminooctane 
hydrochloride_ 
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Figure 16. Nuclear magnetic resonance spectrumt of methyl 
N-(8-aminooctyl) carbamate hydrochlo'ride (in 
D20)» 200 MHZ. . 
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n1ethyl N-(3-aminooctyl) carbamate 
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The NMR of compound 7 (Figure 16) showed the characteristic peaks t:i __ _ 
~~ 
of the compound. Protons A appear as singlet at 3.5 ppm. The down-
field shift of these protons is due to the deshielding effect of the 0. 
B and D protons appear as triplet at 2.95 and 2.85 ppm respectively. C 
______ p_r_S>ions a.Q~~r a&_lDul~~J).].~j:;_be_tween 1.2 and 2.2 PPl'l· _The_ IllasssJ)_ectrUI!l ___ _ 
of this compound (Figure 17) is also consistent with the assigned 
structure showing a molecular ion peak at M + 1 = 203 (M.W. = 202.31). 
As part of this study compounds 3 and 4 were designed to explore 
further the structure-activity relationships associated with changing 
the length of the -CH2- group between the two nitrogens. The results of 
this investigation will give an idea about the distance between the 
cationic binding sites of the enzyme. Furthermore, the results of this 
study, along with those of compounds 2, 5, and 7, could be used to 
design inhibitors with an optimum -CH2- length and with an optimum 
substituent group on the nitrogen. 
Compounds 3 and 4 were synthesized according to scheme 1. A 
solution of acetic anhydride in benzene was added in a dropwise manner 
to stirred solutions of 1,6-diaminohexane or 1,10-diaminodecane (in li 
benzene). Separation of both products from impurities was achieved by 
ion-exchange chromatography. 
The yield of compound 4 (46%) was double that of compound 3 (22%). 
The IR (Figures 18, 19) and NMR (Figures 20, 21) spectra of compounds 3 
and 4 were similar to those of compound 2 and all major peaks were 
accounted for as previously mentioned. Integration of the NMR spectra 
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Figure 20. Nuclear magnetic resonance spectrum' of 
N-acetyl-1,.6-diaminohexane hydrochloride 
(in D20). 200 MHZ. 
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Figure 21. Nuclear magnetic resonance spectrum 1 of 
N-acetyl-1710-diamiriodecane hydrochloride 
(in D20)7 200 MHZ. 
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of compounds 2, 3 and 4 was run and was in agreement with the assigned 
structures. The masses of compound 3 and 4 (Figures 22, 23) are also 
consistent with the assigned structures showing molecular ion peaks at 
M + 1 = 159 (M.W. = 158.21) and 215 (M.W. = 214.31) respectively. 
Compounds 6 and 8 were synthesized and purified by the same 
procedure used for synthesis and purification of compounds 5 and 7 
exc~p_t_'l_,_6-gJamiQQ_hex_ane _ _}l~~-us_eg_:!.I1ste(3.d of .1,8-diaminooctanE.l. The IR 
spectra of compounds 6 and 8 (Figures 24, 25) exhibited all the peaks 
found in the IR spectra of compounds 5 and 7 respectively. The NMR 
spectra (Figures 26, 27) of compounds 6 and 8 appear very similar to 
those of compounds 5 and 7 respectively. The mass spectra of compounds 
6 and 8 (Figures 28, 29) also were consistent with the assigned 
structures and showed molecular ion peaks at M + 1 = 195 (M.W. = 194.30) 
and 175 (M.W. = 174.24) respectively. In addition to the peak at 195 1 
compound 8 shows another peak at 144 (H- O-CH3). 
The size of the active site was investigated further by replacement 
of the acetyl group with a chloroacetyl group. If the active site of 
the enzyme is large enough and can accommodate this group, this compound 
might inhibit the enzyme irreversibly. Irreversible inhibition would be 
dependent upon the presence of a nucleophile at a suitable position on 
the enzyme and the reactivity of the leaving group. Although Cl is less 
reactive than Br and I, it was chosen because its size is smaller than 
the other groups. 
Compound 9 was synthesized according to scheme 3. Direct 
chloroacetylation was tried for the synthesis of compound 9 but was 
unsuccessful. The reason for this is that the chloro group which is 
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Figure 23 _ Chemical ionization (NH3) mass spectrum of 
N-acetyl-1,10-diaminodecane hydrocltl.Ioride_ 
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Figure 24. Infrared spectrum of 
111•mm ~~~ mrm 1 
N -methanesulfonyl-1~6-diaminohexane 
hydrochloride (in mineral oil). 
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Figure 26. Nuclear magnetic resonance spectru~n of 
N-methnesulfonyl-1,6-diaminohexane, 
hydrochloride (in D20l. 200 MHZ. 
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Figure 27. Nuclear magnetic resonance spectrurn of methyl 
N-(6-aminohexyl) carbamate hydrochh,ride (in 
D20), 200 MHZ. 
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that the product will react with the amino group of another or the same 
molecule. 
The key to the successful synthesis of N-chloroacetyl-1,6-diamino-
hexane is the protection of one of the amino group of 1,6-diaminohexane 
by some readily removable group. It is desired that the protecting 
group also favorably alters the solubility properties of the product so 
that its separation from the unsubstituted and disubstituted by-product 
is readily accomplished. The Boo group [2(tert-butoxycarbonyloxyimino)-
2-phenylacetonitril] was chosen because it is removable and renders 
N-Boc-1,6-diaminohexane separable from the unreacted diamine and from 
bis(Boc)-1,6-diaminohexane. Introduction of Boc group is accomplished 
by the addition of a solution of BOC-ON in benzene to a solution of 
1,6-diaminohexane in benzene. N-Boc-1,6-diaminohexane was purified by 
using absorption chromatography. N-Boc-1,6-diaminohexane 
is then treated with chloroacetyl chloride in the presence of triethyl-
amine. N-Boc-N-chloroacetyl-1,6-diaminohexane was crystallized from a 
mixture of benzene and n-hexane (5:3). The Boo group was then removed 
with 3M HCl in ethyl acetate to give N-chloroacetyl-1,6-diaminohexane 
hydrochloride. Finally the product was crystallized from 2-propanol. 
The IR (Figure 30) of compound 9 showed the characteristic 
absorption of the carbonyl group at 1650 cm-1. Broad absorptions are 
observed for (+NH3) N-H stretch at 3300-2000 cm-1 and asymmetric (+NH3) 
N-H bend at 1610 cm-1. The spectrum also showed a weak absorption at 
about 725 cm-1, which is caused by bending vibrations of (CH2) groups. 
The absorption at 780 cm-1 is due to C-Cl stretching vibrations. The 
NMR of compound 9 (Figure 31) showed a singlet at 4 ppm for CH2-Cl. The 
A protons are deshielded by the Cl and by the N and o. B and D protons 
:.._j __ _ 
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showed as triplets at 3.15 and 2.85 ppm respectively. The C protons 
appear as a multiplet between 1.2 and 1.6 ppm. The mass spectrum of 
this compound (Figure 32) is also consistent with the assigned 
structure, showing the M + 1 peak at 193 (M.W. = 192.69) and a peak at 
158 (M = Cl). 
Compound 10 was designed in order to investigate the importance of 
_______ gu:~ _ _!!_ij;_l"_o~~_!l_J.!l_i;~t)_f!_-p()~i_1;ion for spermidine binding. Bioisosteric 
replacement of the N with -CH2- group makes the compound stable toward 
hydrolysis by N-acetylspermidine deacetylase. In addition it is 
reasonable to expect substitution of -CH2- for -NH- to cause no/or small 
change in the affinity of 10 for the enzyme. For these reasons, 
compound 10 was expected to be a potent competitive inhibitor for the 
enzyme. This compound, along with the others, will give a good picture 
of the shape and the binding characteristics of the enzyme active site. 
Compound 10 was synthesized by using the modified methods of Cason, 
Cole and others (93-96) according to scheme 4. The use of the proper 
solvent in the reaction of the acid chloride with the organocadmium 
compounds is very important. Several advantages are found in the use of 
the benzene as solvent compared to ether. First, the precipitate which 
forms in the reaction mixture after addition of the acid chloride is 
less likely to become too thick for efficient stirring if benzene is 
used. Second, the use of the benzene allows a higher reflux temperature 
and accordingly the reaction requires a shorter time in benzene. The 
reaction was run under nitrogen atmosphere in order to avoid degradation 
of Grignard reagent. The ether should be absolute and as a precaution 
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Figure 32 _ Chemical ionization (NH3l mass spe·ctrum of 
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The IR absorption of 10 (Figure 33) showed strong absorption at 
1720 cm-1 (C=O), a broad (+NH3) N-H stretch at 3100-2000 cm-1, and an 
asymmetric (+NH3) N-H bend at 1610 cm-1. The spectrum showed a weak 
absorption at 720 cm-1 which is caused by bending vibrations of the 
70 
The NHR spectrum of 10 is shown in Figure 34. Protons of the 
_!ll~tpp_~l"()'llE_ (~_Pf'Ot()ns) appear as a singlet at 2.1 ppm and B protons 
appear as a triplet at 2 ppm. C protons appear as a multiplet centered 
at 3 ppm and their integration corresponds to 6 protons. D, E, and F 
protons appeared as multiplet at 2, 1.3, and 1.9-3.1 ppm respectively. 
The mass spectrum (Figure 35) of this compound is also consistent with 
the assigned structure, showing a molecular ion peak at M + 1 = 187 (M. 
W. = 186.2) and at 169 (M = HO + 1). 
Pharmacology 
Inhibitory activity determined for all the compounds was performed 
by v. Manneh and P. Marchant in the Department of Physiology and 
Pharmacology at the University of the Pacific. 
Our objective in this study was to design and synthesize potent 
inhibitors to N8-acetylspermidine deacetylase. Inhibition of this 
enzyme in vitro should increase the level of N8-acetylspermidine and may 
be useful to clarify the physiological functions of N8-acetylspermidine 
and the deacetylation process. In order to do this we have studied 
NB-acetylspermidine deacetylase, its substrate specificity and the 
nature of its active site. 
A most important requirement for the work was to determine the Ki 
for the active site probes and the newly synthesized inhibitors. In 
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Infrared spectrum of 
N-(3-aminopropyl)-7-aminoheptane-2...:·one 
hydrochloride (in mineral oil). 
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hydrochloride (in D20), 200 MHZ. 
l·l!.nii!IF·nr!!·~mmnrn I·· 'f! i!· ··I: ... J:fi·i 11 ~ffl!l:uurm.·:li:r~[uFr'mfl ;i 11·:· 1 ·1·· 11 •11 . II iLl 
-.:! 
1\) 















Dixon plots. In this graph inhibitor concentrations are plotted versus 
the reciprocal of the initial velocity at a constant substrate 
concentration. A vertical line from the intersection point of the 
substrate concentrations on the X axis equals the Ki value. By using 
this plot, the nature of the inhibitors (competitive or noncompetitive) 
can be determined, and the Ki values can be directly determined. The in 
_______ vi t_!'~ K~_ v~!_u~~ _ f'~r _ Cl,l_l._the compounds are given in Table 1. 
Manneh et al. have reported that the Ki for acetylputrescine is 
0.80 mM (80). Replacement of the acetyl group in this compound with the. 
butyryl group caused a dramatic decrease in the inhibitory activity of 
the compound (Ki = 29.2 mM) (Figure 36). The change in the Ki value 
corresponds to an about 36-fold decrease in the inhibitory activity 
compared to acetylputrescine. To investigate the importance of the 
nitrogen at the 4-position for the binding of N8-acetylspermidine to the 
enzyme, the nitrogen was replaced by isosteric (-CH2-) group and 
1,8-diaminooctane was synthesized. On the basis of the results obtained 
from the Dixon plot (Figure 37), this compound was found to be a 
comp~titive inhibitor with a Ki value of 0.076 mM. Although the Ki 
( . 
value of this compound is still higher than the Km value for the 
substrate (Km = ·0.01 mM), N-acetyl-1,8-diaminooctane is 10.5 times more 
potent than N-acetylputrescine. 
For further exploration of the active site of the enzyme, methyl 
N-(8-aminooctyl)carbamate and N-methylsulfonyl-1,8-diaminooctane were 
synthesized and their Ki values were determined. These compounds were 
found to be less active than the N-acetyl-1,8-diaminooctane. To our 
surprise methyl N-(8-aminooctyl)carbamate (Ki = 0.26 mM) is 3.5 times 





Inhibition of N -ucetylspennidinedeacetylase by 
structural zmulogs of N-acetylpolyamines. 
-- -- --- ----- -COfiPOOND ___ -. - Ki (mH) 
N 8 -Acetylspennidine 0.01 (Km) 
N-But yrylputrescine 29.2 
N-Acetyl-:-1,6-diaminohexane 0.031 
N-Acetyl-1,8-diaminooctane 0.075 
N-Acetyl-1,1 0-diaminodecane 0.11 
Methyl N-(8-aminooctyl) carbamate 0.26 
N-Hethylsulfonyl-1,6-diaminohexzme 0.37 
N-Hethylsulfonyl-1,8-diDminooctnne 0.65 
Methyl N-(6-aminohexyl) carbamate None 
N-Chloroacetyl-1,6-diaminohexane 0.13 
N-( 3-ami nopropyl) - 7-Dmi noheptane-2-one 0.00018 
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Figure 36. Dixon plots of the reciprocal velocity of 
NB-acetylspermidine deacetylase versus 
N-butyrylputrescine hydrochloride. Effects are 
shown in the presence of 5 ~M ( • ), 10 ~M (b), 
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Dixon plots of reciprocal velocity of 
NB-acetylspermidine deacetylase versus 
N-acetyl-1,8-diaminooctane hydrochloride. 
Effects are shown in the presence of 5 uM ( • ). 









pseudo-irreversible inhibitor). As can be seen from Figure 38, this 
compound is a weak competitive inhibitor for the enzyme. 
Steric hindrance caused by bulky methylsulfonyl and methycarbamate 
groups might be the reason for the decrease in the activity of these 
compounds. The bulkier the substituents are, the larger is the decrease 
of the affinity of the corresponding compound. These results are in 
agre_ement_ with t_hat _obtained from testing of N-butyrylputrescine. These 
results suggest that the size of the active site of the enzyme is 
critical and is too small to accommodate groups larger than the acetyl 
group. 
As part of the study, N-acetyl-1,6-diaminohexane and N-acetyl-1,10 
diaminodecane were synthesized to explore the structure-activity 
relationship with changing the length of the -CH- group, separating the 
two basic nitrogens. Our results revealed that separation of the 
terminal amines with 10 carbons caused a decrease in the inhibitory 
activity of the compound (Ki = 0.11 mM). On the other hand, separation 
of the terminal amines with 6 carbons, resulted in 2.5-fold increase in 
the activity of this compound (Figure 39, Ki = 0.031 mM) compared with 
that of N-1,8-diaminooctane. 
Recplacement of the acetyl group of the N-acetyl-1,6-diaminohexane 
with methylsulfonyl and with methyl carbamate groups caused a decrease 
in the activity of those compounds. These results are in agreement with 
those of N-methylsulfonyl-1,8-diaminooctane and methyl N-(8-aminooctyl)-
carbamate. 
Substitution of the acetyl group of N-acetyl-1,6-diaminohexane with 
a chloroacetyl group accounted for about a 4-fold decrease in the 
activity of this compound (Ki = 0.13 mM). The reason for this decrease 
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Figure 38. Dixon plots of the reciprocal velocity 01f 
NO-acetylspermidine deacetylase versu.s methyl 
N-(8-aminooctyl) carbamate hydrochlodde. 
Effects are shown in the presence of 3.7 pM ( • ). 
7..4 pM (6.). and 14.8 pM (o) of substr21.te 
concentrations. · 
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Dixon plots of the reciprocal velocity of 
NB-acetylspermidine deacetylase versus 
N -acetyl-1.6-diaminohexane hydrochlorid•~. 
Effects are shown in the presence of 3.7 11M ( • ). 
7.4 JIM ( 8 ). and 14.8 l1M ( o) of substrate 
concentrations. 






rl:mwar.:tJI[II.II:IU:::Ju·.:,::i.mmm:mm:J[IJ.IIr 11.:.m: :.:;: t:: 
81 
may be due to the decrease in the affinity of the compound for the 
active site of the enzyme caused by the increased bulk on the acetyl 
group. No irreversible inhibition of the enzyme was observed even after 
longer (30 min) incubation times were used. It is possible that the 
failure of the chloroacetyl compound to alkylate the enzyme is due to 
the low reactivity of this group. 
___________ I_t_ is li~J]._~!!~!iP_t,_hat Br and I are better lea.ving groups than the ____ _ 
Cl group. However, it is not rational to synthesize bromo or iodo 
derivatives since these derivatives are much more bulky than the chloro 
derivatives, thus they would be expected to have a greater decrease in 
affinity for the enzyme active site. The results of this study support 
our conclusion in that any substituent on the terminal nitrogen with 
groups larger than the acetyl group is detrimental for the activity of 
the compound. As indicated earlier, it seems that the binding site of 
the enzyme is small and cannot sterically accommodate any added bulk. 
To investigate the importance of the N8 for the binding of the 
NB-acetylspermidine to the enzyme, the nitrogen was replaced with a 
-CH2- group. As predicted this compound was found to be the most 
effective inhibitor for the enzyme among the compounds studied in this 
project. The Ki value determined for this compound (Ki = 0.18 uM; 
Figure 40) is 55 times less than the Km value of the substrate (Km = 
0.01 mM). It is apparent that bioisosteric replacement of the nitrogen 
with -CH2- group has a profound effect on the activity of compound 10. 
The large increase in the activity is due to the following reasons. 
First, the affinity of the compound is not decreased by such substitu-
tion. Second, the bioisosteric replacement makes the compound resistant 
to the action of the enzyme. Third, the compound binds much more 
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Dixon plots of the reciprocal velocity of 
NB-acetylspermidine deacetylase v'ersus 
N-(3-aminopropyl)-7 -aminoheptane-2-one 
hydrochloride. Effects are shown in the presence 
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tightly to the enzyme (through the carbonyl group and through the 
nitrogens at 1 and 4 positions) than N-acetyl-1,6-diaminohexane and 
N-acetyl-1,8-diaminooctane. 
From the above results, it is clear that the active site of 
NB-acetylspermidine deacetylase is not large enough to accommodate 
groups bigger than an acetyl group. This study also shows that the 
number of the carbons separating the two nitrogens influences the 
affinity of the inhibitors for the enzyme. 
On the basis of the results of this investigation, and other 
83 
results obtained in our laboratory, a hypothetical model for the active 
site of N8-acetylspermidine deacetylase is shown in Figure 41. The 
distance between the binding sites of N1-N4, N4-N8 and N1-N8 is about 5, 
6.2 and 8.9 A respectively. This model explains why N-acetyl-1, 
6-diaminohexane is a more potent inhibitor than N-acetyl-1,8-diamino-
octane. According to this model, compound 10 binds more tightly and has 
higher affinity than all the compounds tested in this project. Compound 
10 is the most potent and specific inhibitor for the N8-acetylspermidine 
deacetylase reported. This compound will be used as a lead compound to 
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The polyamines putrescine, spermidine and spermine play an essential 
role in cell growth and differentiation. Spermidine is metabolized to 
N1;N8-acetylspermidine by two different enzymes (spermidine N1-acetyl-
transferase and spermidine N8-acetyltransferase). The concentrations of 
NB~acetyispermidine-in liver,-kidney and spleen are lower than those of 
spermidine or N1-acetylspermidine. NB-Acetylspermidine is deacetylated 
by an enzyme in the 100.000 x g supernatant of rat liver. 
One approach for determining the physiological functions of 
N8-acetylspermidine is to increase its concentration in the tissues. In 
order to do this, a series of N8-acetylspermidine analogues were designed 
and synthesized to inhibit the N8-acetylspermidine deacetylase. 
The nature of the inhibition and the Ki values for the inhibitors 
were determined from Dixon plots. N-Butyrylputrescine was the least 
effective inhibitor (Ki = 29.2 mM). Bioisosteric replacement of N4 of 
NB-acetylspermidine with a -CH2- group resulted in an increase in the 
inhibitory activity (Ki = 0.075 mM). 
Separating the terminal nitrogens with 10 carbons resulted in a 
decrease in the potency of the compound (Ki = 0.11 mM). In contrast, 
decreasing the distance between the terminal amines to 6 carbons 
resulted in 2.5 fo~d increase in the inhibitory activity compared with 
N-acetyl-1,8-diaminooctane. 
The active site of the enzyme was investigated by substitutions of 
the acetyl group with larger groups (methane sulfonyl, carbamyl and 




the inhibitors. These results are in agreement with those of N-Butyryl-
putrescine. It seems that the active site of the enzyme is small and it 
is not large enough to accommodate groups larger than the acetyl group. 
Results obtained from the above studies were used to design and 
synthesize compound 10. In this inhibitor the bioisosteric replacement 
of the N8 of N8-acetylspermidine with a -CH2- group was made. In vitro 
studies showed this compound to be the most potent inhibitor for 
----- - - -- -NH:.acetylspermici-ine-d.;a~-etylase yet to be reported ( Ki = o. ooo 18 mM) • 
Based on these results and others obtained from Dr. Blankenship's 
labratory, a hypothetical model for the enzyme is drawn. The active 
site of the enzyme is shown to contain zinc. The distances between the 
sites on the enzyme which are important for binding the substrate are 
estimated. Useful information obtained from this study about the 
catalytic mechanism and about the binding sites of the enzyme will be 
used to synthesize more potent inhibitors for the enzyme. 
', 
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